Videssa® Breast Cancer Blood Test

Giving Peace of Mind by Helping Rule Out Breast Cancer

Coming in 2023 the only blood test to rule out breast cancer with >98% accuracy in women with suspicious imaging findings, irrespective of breast density.

A simple blood test to detect breast cancer with high accuracy in women with abnormal imaging findings

  • A protein-based blood test combining Serum protein biomarkers (SPBs) with Tumor Associated Autoantibodies (TAAbs)
  • Previously CLIA certified
  • Launching in 2023 as an LDT in USA

Gain greater confidence in ruling out cancer for BIRADS 3 & 4 with high accuracy irrespective of tissue density.*

*Following identification of an abnormal imaging finding.


Challenges with Detection

If your mammogram showed a BIRADS 3 or 4, would you like to have the option of choosing a simple blood test prior to biopsy?

Soon you will be able to ask your doctor if this is right for you.

Less pain, more gain. With fewer unnecessary biopsies, your experience is less stressful.

No false negatives when combined with standard of care and imaging.


30 million

women undergo mammography annually in the United States

15.5 million

women undergoing mammography have dense breasts

32 states

have passed legislation that patients be informed of their breast density

The Videssa® Breast Solution

Videssa Breast is the first blood test of its kind to detect the presence or absence of breast cancer in women with abnormal or difficult-to-interpret mammographic findings. When used in combination with imaging, Videssa Breast can improve diagnostic accuracy and provide greater confidence and clarity when clinical assessment is challenging. Videssa Breast offers clarity for healthcare providers who must navigate complex decisions in women who present with difficult-to-interpret findings.

Sign up for the latest news on Videssa and breast cancer research updates.